ABSTRACT

Introduction

Glioblastoma multiforme is the most common and the most aggressive primary brain tumor, with a median survival of 14 months. This dismal prognostic has turned research toward nanomedicine as a new therapeutic approach that can deliver therapeutic compounds to GBM.

Areas covered

The review covers recent advances in the targeted delivery of therapeutic compounds to glioblastoma tumors. To reach the tumors, nanocarriers and their cargo should cross the Blood-Brain Barrier (BBB) standing between the bloodstream and the tumor. For that purpose, different peptides to facilitate BBB crossing have been added to the nanoparticles. As result, an increase in BBB crossing was observed. Other significant effort has been devoted to selectively target direct the nanocarrier and its cargo to GBM tumors. Once again, targeting peptides have been used.

Expert opinion

Besides significant advances, a more successful design of nanocarriers for efficient BBB crossing and delivery of diagnostic and/or therapeutic molecules to CNS will be needed to achieve efficient nanomedicine-based therapeutics for glioblastoma. This will require a significant effort in improving the chemical architecture of nanocarriers, identifying the critical design parameters that might play a key role in facilitating both BBB crossing and GBM selective targeting.

中文翻译：

---

通过纳米颗粒药物递送治疗难治性胶质母细胞瘤的潜在进展。

摘要

介绍

多形胶质母细胞瘤是最常见，最具侵略性的原发性脑肿瘤，中位生存期为14个月。这种令人沮丧的预后使研究转向了纳米医学，这是一种可以向GBM输送治疗性化合物的新治疗方法。

覆盖区域

综述涵盖了靶向治疗化合物向胶质母细胞瘤肿瘤的靶向递送的最新进展。为了到达肿瘤，纳米载体及其货物应越过位于血液和肿瘤之间的血脑屏障（BBB）。为此目的，已经将促进BBB穿越的不同肽添加至纳米颗粒。结果，观察到BBB交叉增加。已经进行了其他重要的努力，以选择性地将纳米载体及其载物直接靶向GBM肿瘤。再次，使用了靶向肽。

专家意见

除了取得重大进展外，还需要更成功的纳米载体设计，用于有效的BBB穿越以及将诊断和/或治疗性分子递送至CNS，以实现基于胶质母细胞瘤的高效基于纳米药物的治疗剂。这将需要付出巨大的努力来改善纳米载体的化学结构，确定可能在促进BBB穿越和GBM选择性靶向中起关键作用的关键设计参数。